Savara (SVRA) Earnings Date & Reports

Key Takeaways

• Savara reported a third-quarter 2026 net loss of $42.99 million, up from $29.56 million in the same period a year earlier.
• Loss per share came in at $0.17, versus $0.14 in Q3 2025 and slightly wider than the consensus estimate of roughly $0.16.
• Total operating expenses rose to $43.54 million, driven by higher research and development (R&D) and general and administrative (G&A) spending ahead of a potential commercial launch.
• Cash and short-term investments totaled about $129.6 million at September 30, 2026, down from roughly $235.7 million at the end of 2025.
• The company's MOLBREEVI Biologics License Application (BLA) carries a Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to discover AI-driven trading signals and market ideas.

Earnings Context and Why It Matters

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its lead candidate, MOLBREEVI (molgramostim), under review for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. Because the company has not yet generated product revenue, its quarterly earnings primarily reflect operating expenses and cash burn rather than commercial performance. This report matters less for top-line results and more for what it reveals about the company's financial runway and spending trajectory as it approaches a potential U.S. approval. With a regulatory decision due in November 2026, investors are watching whether Savara has adequate capital and disciplined cost management to support a launch.

Reported Results

For the third quarter ended September 30, 2026, Savara reported a net loss of $42.99 million, compared with a net loss of $29.56 million in the prior-year quarter. Basic and diluted loss per share from continuing operations was $0.17, up from $0.14 a year earlier. For the nine months ended September 30, 2026, the net loss totaled $120.50 million, compared with $86.60 million in the same period of 2025, with loss per share of $0.47.

Operating expenses for the quarter reached $43.54 million, up from $30.26 million a year ago. Research and development (R&D) expenses rose to $24.95 million from $20.59 million, while general and administrative (G&A) expenses increased to $18.54 million from $9.63 million. As a pre-revenue company, Savara reported no meaningful product sales, and the results were broadly in line with expectations for a clinical-stage biotech that is investing ahead of a potential approval.

On the balance sheet, cash and cash equivalents stood at $29.81 million and short-term investments at $99.84 million as of September 30, 2026, down from $33.18 million and $202.52 million, respectively, at December 31, 2025.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like Savara, it offers a structured way to surface new ideas across the broader healthcare and biotech landscape.

Market Reaction and Investor Sentiment

Savara's shares have historically been sensitive around earnings releases, with the company missing consensus earnings per share (EPS) estimates in each of its last eight reported quarters. The Q3 2026 report continued that pattern, with the $0.17 loss per share coming in modestly wider than the consensus estimate of approximately $0.16. However, for a pre-revenue biotech, the quarterly miss has drawn less attention than the larger binary catalyst ahead: the upcoming FDA decision on MOLBREEVI.

Investor sentiment heading into the report was largely shaped by the regulatory timeline rather than by the operating results themselves, and that dynamic is expected to persist. The widening net loss reflects a deliberate ramp-up in spending to prepare for commercialization, which markets generally view as consistent with the company's stated strategy.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst for Savara is the PDUFA target action date of November 22, 2026 for the MOLBREEVI BLA in autoimmune pulmonary alveolar proteinosis (aPAP). A U.S. approval would represent the company's first commercial product and a major inflection point.

Beyond the FDA decision, investors should monitor regulatory progress in other regions. The company has stated that its Marketing Authorization Applications (MAAs) are under review by the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), with decisions expected in Q1 2027 and Q4 2026, respectively.

On the financial side, cash management will remain a key area of focus. With cash and short-term investments of roughly $129.6 million at the end of the quarter, investors will be watching how quickly that runway is consumed, particularly if the company moves toward a commercial launch. Rising R&D and G&A expenses suggest the cost base may continue to climb, making disciplined execution and potential future financing decisions important themes to monitor. As always, these considerations are informational in nature and should be weighed alongside each investor's own research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations